Gastrointestinal (GI) cancers affect millions of people worldwide and include cancer of the esophagus, stomach, liver, pancreas, gallbladder, colon, and rectum. These are some of the most aggressive and difficult-to-treat cancers, often diagnosed at an advanced stage. Among them, colorectal cancer ranks as the third most common cancer globally, with over 1.9 million new cases diagnosed each year, according to the World Health Organization. 

Over the past decade, the field of oncology has undergone a remarkable transformation. The latest treatments for gastrointestinal cancer are no longer one-size-fits-all. From targeted therapies that pinpoint cancer at the molecular level to immunotherapy that awakens the body’s defenses, we’re now witnessing what could only be described as a new era in cancer care.

In this blog, we explore the latest treatments for gastrointestinal cancer, focusing on how innovations like targeted therapies, immunotherapies, and new drugs are transforming patient outcomes.

Personalised Medicine for GI Cancer

One of the most significant advancements in GI cancer therapy is the shift toward personalised or precision medicine. This approach enables oncologists to treat cancer based on its molecular and genetic characteristics rather than its anatomical location alone.

For GI cancers, key biomarkers like KRAS, BRAF, HER2, and microsatellite instability (MSI) play an essential role in therapy selection. For example, colorectal cancers with wild-type RAS genes respond to EGFR inhibitors, while HER2-positive stomach cancers are eligible for HER2-targeted treatments. This shift is at the core of the latest treatments for gastrointestinal cancer, bringing hope where little existed before.

According to Dr. Deep Goel, “The shift toward personalised medicine in GI cancer treatment has been revolutionary, allowing us to tailor therapies based on the genetic profile of each patient. This has significantly improved treatment outcomes and reduced unnecessary side effects.

Targeted Therapies for GI Cancers

One of the most promising directions in oncology is the development of targeted therapy for GI tumors. These treatments block the growth and spread of cancer by interfering with specific molecules involved in tumor progression.

Some prominent targeted therapies in GI oncology include:

• HER2 inhibitors like trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu), used in HER2-positive gastric and gastroesophageal cancers.
• BRAF inhibitors such as encorafenib (in combination with cetuximab) for BRAF-mutant metastatic colorectal cancer.
• Anti-angiogenic agents like bevacizumab (Avastin) and ramucirumab which prevent tumors from developing new blood vessels.

By hitting specific targets rather than attacking all rapidly dividing cells, these therapies offer improved efficacy with fewer side effects—a substantial leap forward in the advancements in GI cancer therapy.

Dr. Deep Goel emphasises, “Precision medicine and molecular profiling are changing the way we approach GI cancer treatment. By understanding the genetic mutations driving a patient’s cancer, we can offer highly effective and customised treatment strategies.”

“I came to Dr. Deep Goel after my colon cancer had recurred, and I had almost given up hope. He not only offered a comprehensive treatment plan but also explained every step with patience and clarity. His combination of advanced surgical techniques and targeted therapy turned things around for me. I’m now in remission and feeling stronger every day. Dr. Goel gave me a new lease on life,” says one of the patients of Dr. Goel.

Immunotherapy for Gastrointestinal Cancers

Another major leap in cancer treatment has been the use of immunotherapy for gastrointestinal cancers. Immunotherapies, particularly checkpoint inhibitors, work by removing the “brakes” from the immune system, allowing it to recognise and destroy cancer cells more effectively.

Checkpoint inhibitors like pembrolizumab and nivolumab have changed the prognosis for many patients with specific tumor subtypes:

• MSI-H/dMMR Colorectal Cancer: These tumors respond remarkably well to immunotherapy, often resulting in durable responses, even in advanced stages.
• Esophageal and Gastric Cancers: Immunotherapy, either alone or in combination with chemotherapy, has become a standard option for some advanced cases.
• Hepatocellular Carcinoma (HCC): Atezolizumab combined with bevacizumab has been approved for first-line treatment of advanced liver cancer, offering a survival advantage over traditional therapies.

Though not all GI cancers respond equally to immunotherapy, ongoing research continues to uncover new biomarkers and combinations that may expand its applicability. The more we understand about the tumor-immune environment, the more patients will benefit from this approach.

New Drugs for GI Cancer

Pharmaceutical innovation is fueling a surge of new drugs for GI cancer, some already approved and others in advanced clinical trials. These novel agents offer hope, particularly for patients who have exhausted first- and second-line therapies.

Noteworthy additions to the therapeutic arsenal include:

• Trifluridine/tipiracil (Lonsurf): Approved for refractory metastatic colorectal cancer, this oral agent adds a survival benefit with manageable toxicity.
• Zolbetuximab: A monoclonal antibody targeting Claudin 18.2, a protein highly expressed in some gastric cancers. Early trial results show promise in improving survival rates.
• NTRK Inhibitors: Larotrectinib and entrectinib are tumor-agnostic drugs that target NTRK gene fusions, rare but actionable mutations seen in various GI tumors.

Each of these drugs represents a significant step forward, especially for patients with limited treatment options.

Liquid Biopsies and Biomarker Testing

Another critical development in advancements in GI cancer therapy is the rise of liquid biopsies and advanced biomarker testing. These tools help doctors understand the tumor’s biology through a simple blood sample, reducing the need for invasive tissue biopsies.

Liquid biopsies can detect circulating tumor DNA (ctDNA), which can:

• Identify genetic mutations
• Monitor treatment response
• Detect recurrence early

In parallel, biomarker testing is becoming a routine part of care for GI cancers. Knowing a tumor’s HER2 status, MSI status, or RAS/BRAF mutation status can guide decisions on the latest treatments for gastrointestinal cancer, including targeted therapies and immunotherapies. As these tests become more accessible, personalised treatment will continue to improve.

Combining Treatments for Better Results

In modern cancer care, combining different therapies is often more effective than relying on a single approach. Many treatment regimens for GI cancers now involve integrating surgery, chemotherapy, immunotherapy, and targeted therapy.

Examples of combination approaches include:

• Total Neoadjuvant Therapy (TNT): In rectal cancer, this strategy involves giving chemotherapy and radiation before surgery to shrink the tumor and improve surgical outcomes.
• Esophageal cancer: Combining chemotherapy, immunotherapy, and surgery has improved survival in locally advanced cases.
• Liver and biliary tract cancers: Interventional techniques like transarterial chemoembolisation (TACE) are used alongside systemic therapies.

This collaborative, multidisciplinary model of care ensures that patients receive the most effective and personalised treatment possible.

Another patient of Dr. Deep shared, “After being diagnosed with stage 3 stomach cancer, I was devastated. Dr. Deep Goel and his team gave me hope by recommending a combination of targeted therapy and immunotherapy. Within months, my tumor size had reduced significantly. I am grateful for the advancements in GI cancer treatment that gave me a second chance at life.”

Looking Ahead

The field of GI oncology is advancing at an unprecedented pace. The latest treatments for gastrointestinal cancer now emphasise not just attacking the disease but understanding its biology, anticipating resistance, and preserving the patient’s dignity throughout treatment.

As we continue to unlock the potential of targeted therapy for GI tumors, refine the application of immunotherapy for gastrointestinal cancers, and introduce new drugs for GI cancer, the outlook becomes more hopeful than ever.

For patients and physicians alike, these innovations mark a new standard of care—one that is smarter, more compassionate, and more effective.

FAQs

1. What is a liquid biopsy?

It is a non-invasive blood test that detects circulating tumor DNA (ctDNA) to monitor cancer progression and treatment response.

2. How effective is combining immunotherapy with chemotherapy?

Combination therapies are showing better results in several GI cancers, offering longer survival and better tumor response.

3. Are these advanced treatments available in India?

Yes, most advanced treatments, including immunotherapy, targeted therapy, and biomarker testing, are widely available at top Indian hospitals.

4. Is surgery still needed with modern treatments?

Yes, surgery is often combined with other treatments for better results, especially in colorectal, esophageal, and liver cancers.

5. What lifestyle changes can help during GI cancer treatment?

Healthy eating, regular physical activity (as tolerated), stress reduction, and quitting tobacco and alcohol can support recovery and treatment effectiveness.

Explore More Blogs: Is GI Cancer hereditary?